SNPHY - Santen Pharmaceutical Co. Ltd. GAAP EPS of ¥54.11 revenue of ¥199.8B February, 07 2023 09:26 AM Santen Pharmaceutical Co. Ltd. ADR Santen Pharmaceutical Co., Ltd. press release ( OTCPK:SNPHY ): Q3 GAAP EPS of ¥54.11. Revenue of ¥199.8B (+2.0% Y/Y). For further details see: Santen Pharmaceutical Co., Ltd. GAAP EPS of ¥54.11, revenue of ¥199.8B